Skip to main content
Kintor Pharmaceutical Limited logo

Kintor Pharmaceutical Limited — Investor Relations & Filings

Ticker · 9939 ISIN · KYG5273B1077 HKEX Manufacturing
Open in API
Filings indexed 313 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country HK Hong Kong
Listing HKEX 9939

About Kintor Pharmaceutical Limited

http://www.kintor.com.cn

Kintor Pharmaceutical Limited is a clinical-stage novel drug developer specializing in the research and development of innovative small molecule and biologic therapeutics. The company focuses on addressing substantial unmet medical needs within dermatology and oncology, with a particular emphasis on androgen receptor (AR)-related diseases. Kintor maintains a robust, multi-channel pipeline featuring proprietary technologies such as AR antagonists, AR-PROTACs, mTOR inhibitors, and the licensed ALK-1 antibody project. Key therapeutic targets include hair loss (AGA), acne, prostate cancer, and liver cancer. The company utilizes a global integrated R&D platform to develop combination therapies and has initiated commercialization efforts for cosmetic treatments derived from its pipeline.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return filed with the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for Kintor Pharmaceutical Limited. It details authorized and issued share capital, public float sufficiency confirmation, and confirms compliance with listing rules. The document is a regulatory submission about share capital and share movements, not a financial report, earnings release, or management discussion. It is not an announcement of a report but a regulatory filing itself. It does not fit into categories like Annual Report, Earnings Release, or Capital/Financing Update. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2026-05-06 English
ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025
Environmental & Social Information Classification · 100% confidence The document is titled as the "Environmental, Social and Governance Report 2025" issued by Kintor Pharmaceutical Limited. It explicitly states that it is an ESG report for the year ended 31 December 2025. The content includes sections on environmental protection, social responsibility, corporate governance, and sustainability efforts. It references compliance with the ESG Reporting Code under the Hong Kong Stock Exchange Listing Rules. The document does not contain financial statements or earnings data but focuses on ESG topics such as emissions, resource use, labor standards, anti-corruption, and community engagement. This matches the definition of an Environmental & Social Information report (ESG report). The document length is substantial (15,000 characters), indicating it is the full report, not just an announcement. Therefore, the correct classification is Environmental & Social Information (SR).
2026-04-29 English
ANNUAL REPORT 2025
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2025' and contains extensive content typical of an annual report, including company profile, chairman's statement, financial highlights, business highlights, management discussion and analysis, profiles of directors and senior management, corporate governance report, directors' report, independent auditor's report, consolidated financial statements, and notes to the financial statements. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. The presence of detailed financial data, management analysis, and auditor's report confirms this is the official yearly report covering company activity and full financial performance for the fiscal year 2025. Therefore, the document fits the definition of an Annual Report (10-K).
2026-04-29 English
VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE
Capital/Financing Update Classification · 85% confidence The document is a voluntary business update announcement by Kintor Pharmaceutical Limited. It provides recent sales performance data and business segment growth but does not contain comprehensive financial statements or detailed financial analysis. The document length is 3481 characters, which is relatively short and typical for an announcement rather than a full report. There is no indication that this is an earnings release with key financial highlights only, nor is it a full annual or interim report. It is not a regulatory filing or certification. The content focuses on business progress and sales updates, which aligns with a Capital/Financing Update or business update announcement. Given the nature of the content and the voluntary announcement format, the best fitting category is Capital/Financing Update (CAP).
2026-04-20 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 90% confidence The document is a routine monthly listing rule return (Form FF301) submitted to the Hong Kong Exchange under Chapter 19B, detailing authorised share capital, issued shares, treasury shares and public float sufficiency. It is not an earnings release, annual report, capital raising announcement, nor a meeting or voting document. There is no specific category for monthly listing returns, so the appropriate classification is the fallback “Regulatory Filings” (RNS).
2026-04-01 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025
Earnings Release Classification · 91% confidence The document is an “Annual Results Announcement for the Year Ended 31 December 2025” filed on the Hong Kong Stock Exchange, containing financial highlights, loss/profit figures, business highlights, and Management Discussion & Analysis. It constitutes the initial announcement of annual financial results rather than the full annual report. This matches the definition of an Earnings Release (ER). FY 2025
2026-03-30 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.